Skip to main
MMED

MMED Stock Forecast & Price Target

MMED Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Minimed Group is a leader in the diabetes technology market, recognized for their innovative and comprehensive product offerings. With a strong focus on glucose control and a promising product pipeline, analysts have set a $25 price target for the company. Their global presence and unique market position make them a solid investment in the growing MedTech industry.

Bears say

Minimed Group is facing intense competition in the diabetes medical technology industry, with multiple companies offering similar products and solutions. While they have clear differentiation and early clinical data, it will be crucial for the company to execute successfully on its new product launches to stay competitive. MiniMed has shown effective execution on its regulatory approval plans and timelines, but approvals and timely launches remain a risk. Additionally, reimbursement access is increasing, but out-of-pocket costs and workflow/technology burden may still be barriers for patients.

MMED has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiniMed Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiniMed Group Inc (MMED) Forecast

Analysts have given MMED a Buy based on their latest research and market trends.

According to 9 analysts, MMED has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $22.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $22.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiniMed Group Inc (MMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.